Therapeutic Antibodies – News and Features

Research shows that some lung cancer cells retain a “memory” of the healthy cell where they came from — one that might be exploited to make an emerging type of lung cancer treatment called KRAS inhibition more effective.

A diverse array of biological medicines are now used to prevent and treat a wide range of illnesses. This article will discuss the development of cell lines in biopharma and will touch on key considerations, such as future manufacturability.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.

Host cell proteins can prove problematic for the development of novel biopharmaceuticals. This article will highlight some of the latest advances in host cell analysis strategies and how they are being implemented.

A new approach to cancer treatment uses IgA antibodies to target and destroy tumor-promoting molecules deep within cells and has been described as a more precise, long-lasting and less toxic approach.

The gene therapy landscape is dynamic and constantly shifting. In this article, we will review major advances in disease modification for illnesses that presently still lack effective treatments, as well as some challenges and approaches to overcome them.

A bispecific cancer drug that targets two checkpoint proteins is potentially more effective and at least as safe as standard therapies, reports a phase one trial.

A novel therapeutic approach that combines human epidermal growth receptor factor 2 (HER2)-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor growth.

Measuring ctDNA could offer a new approach to identifying non-small cell lung cancer patients in greater need of additional treatments during immunotherapy.

Biomarkers can potentially aid patient management across the stages of their disease course. This article will review advances in computationally-driven biomarker discovery, including from metabolomics datasets, for complex, multifactorial diseases.